Get the Stockscreener App
0.00
0.00%
0.00
Vitro Biopharma, Inc. stock is traded at $0.00, with a volume of 0.
It is up +0.00% in the last 24 hours and up +0.00% over the past month.
Vitro Biopharma is an innovative biotechnology company focused on developing Wharton's jelly-derived cell therapies for autoimmune diseases and inflammatory disorders. Their goal is to become a leader in developing differentiated product candidates in a rapid and efficient manner for the immunology and inflammatory market.
See More
Previous Close:
$0.00
Open:
$0
24h Volume:
0
Relative Volume:
Market Cap:
$N/A
Revenue:
$1.65M
Net Income/Loss:
$-5.91M
P/E Ratio:
0.00
EPS:
-0.1707
Net Cash Flow:
$-3.03M
1W Performance:
+0.00%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$0.00
Vitro Biopharma, Inc. Stock (VTRO) Company Profile
Name
Vitro Biopharma, Inc.
Sector
Industry
Phone
(720) 859-4120
Address
4621 TECHNOLOGY DRIVE, GOLDEN
Compare VTRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTRO
Vitro Biopharma, Inc.
|
0.00 | 0 | 1.65M | -5.91M | -3.03M | -0.1707 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Vitro Biopharma, Inc. Stock (VTRO) Latest News
Vitro Biopharma Announces Early 2016 Results: Increased Revenue and Expansion Activities to Fuel Growth - ACCESS Newswire
Vitro Diagnostics (OTCMKTS:VODG) & Fennec Pharmaceuticals (NASDAQ:FENC) Head to Head Survey - Defense World
Dealmaking Quarterly Statistics, Q2 2022 - insights.citeline.com
COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product - Yahoo Finance
Vitro Biopharma Products Advance Pancreatic Cancer Research - ACCESS Newswire
Vitro Biopharma Revenues Increase in Early 2014: Plans Trials of Endogenous Stem Cell Activation for Therapeutic Benefit - ACCESS Newswire
Best Biotech Stocks to Buy in 2025 - The Motley Fool
Vitro Biopharma Announces Advances in Stem Cell Therapy without Transplants - ACCESS Newswire
Vitro Diagnostics (OTCMKTS:VODG) vs. HilleVax (NASDAQ:HLVX) Financial Review - Defense World
Reviewing Cyclo Therapeutics (NASDAQ:CYTH) and Vitro Diagnostics (OTCMKTS:VODG) - Defense World
Financing Quarterly Statistics, Q4 2024 - Citeline
Vitro Biopharma, Inc. Reports Earnings Results for the Full Year Ended October 31, 2024 - Marketscreener.com
Vitro Biopharma Inc. January 31st 2021, 1st Quarter ended Financial Results of Operations and Shareholder Letter - ACCESS Newswire
Vitro Diagnostics (OTCMKTS:VODG) & Inhibrx (NASDAQ:INBX) Head to Head Review - Defense World
Biopharmaceutical Culture Media Market Insight 2025 is Exhibitin - WICZ
In Vitro Diagnostics (IVD) Market Size to Surpass USD 157.56 Billion by 2034 - BioSpace
Vitro Diagnostics (OTCMKTS:VODG) and Tectonic Therapeutic (NASDAQ:TECX) Critical Comparison - Defense World
6 cultured meat companies making waves - Labiotech.eu
Simulations Plus and Partners Awarded New FDA Grant to Validate In Vitro-In Vivo Extrapolation Methods for Complex Formulations - Business Wire
Biopharmaceutical Culture Media Industry Trends & Drivers - Economica
Top 5 In-Vitro Diagnostics [IVD] Companies, Worldwide by 2024 - Fortune Business Insights
FDA’s lab-developed test rule could be first test of agency’s power post-Chevron - BioPharma Dive
Vitro Biopharma, Inc. announced that it has received $0.3 million in funding - Marketscreener.com
A biotech working on a new approach to IVF raises $33M in fresh funding - BioPharma Dive
New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024 - Yahoo Finance
GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications - PR Newswire
FDA defends lab test rule, as critics fear industry upheaval - BioPharma Dive
21 Atlanta Biotech Companies Making Waves in the Life Sciences Sector - Built In
Fapon Empowers Indian IVD Manufacturers at Medical Fair India 2024 - PR Newswire
Swiss investment firm denies acquisition bid for Boryung Biopharma - KBR
Asep Medical Holdings Inc. Signs Joint Venture Agreement with Leading Chinese Medical Diagnostics Company Sansure Biotech Inc. - PR Newswire
Regen BioPharma, Inc. Selects Contract Research Organization to Assist in DuraCAR Experiments - StockTitan
Siemens Healthineers considering $8 billion sale of in vitro diagnostics unit, announces 300 layoffs - DOTmed HealthCare Business News
Navigate BioPharma Services, Inc. Announces Collaboration with BD (Becton, Dickinson and Company) to Advance Capabilities for Clinical Phases of Drug Development - PR Newswire
In Vitro Fertilization (IVF) Market Size & Share to Surpass $1296.47 Mn by 2030 | Vantage Market Research - Yahoo Finance
IPO Update: Vitro Biopharma Aims For $10 Million U.S. IPO (VTRO) - Seeking Alpha
Startup aims to make lab-grown human eggs, transforming options for creating families - NPR
VTRO IPO NewsStem cell biotech Vitro Biopharma sets terms for $10 million IPO - renaissancecapital.com
CYPRE’S 3D in Vitro Platform Advances New Insights into the Tumor Microenvironment, Drives Data in 30 Days for Clients - Business Wire
Global Stem Cells Market Research Report 2023: Implications - GlobeNewswire
This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF - STAT
Who are the leading innovators in in-vitro T-cell activation for the pharmaceutical industry? - Pharmaceutical Technology
Vitro Biopharma, Inc. announced a financing transaction -January 05, 2023 - Marketscreener.com
In Vitro Glycoengineering – Suitability For BioPharma Manufacturing - BioProcess Online
SeQure Dx Emerges From Stealth Mode to Fulfill the Promise of On-Target Gene Editing Therapies for Biopharma Partners, Physicians, and Patients - Business Wire
FUJIFILM Irvine Scientific PRIME-XV Stem FreezIS DMSO-Free Cryopreservation Medium to be Used in FDA-Authorized Clinical Trial - Business Wire
Is Vitro Biopharma Inc. IPO a Good Buy? - Benzinga
Vitro Biopharma Names Chris Furman Chief Executive Officer - Yahoo Finance
Understanding the promising opportunities for in-vitro diagnostics companies in the next decade - IQVIA
The 10 most innovative biotech companies in 2022 - Fast Company
Business of Biotechniques 2022 - BioTechniques
Vitro Biopharma, Inc. Stock (VTRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.00%
Cap:
|
Volume (24h):